Paul.jnxy
Mogs me
- Joined
- Jan 10, 2026
- Posts
- 4,057
- Reputation
- 5,432
LOL he contradicting himself
Niebvll
Stop the rHGH Cope
- Joined
- Sep 4, 2025
- Posts
- 12,230
- Reputation
- 17,701
Smartest niggaa with <1:1 p/rLOL he contradicting himself
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #53
Vosoritide is a downstream signaling inhibitor. It does not stop the FGFR3 gene directly, but rather neutralizes its effects further down the cell's pathway. It’s an indirect inhibitor. No doctor or scientist is arguing about this. Obviously it’s not directly inhibiting the receptor but the effects are the same as any other inhibitor. This is already something everyone is already well aware of. But arguing that it’s not considered a fgfr3 inhibitor in any way and shouldn’t have a place in this thread is illogical.
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #54
Jester #2 your boyfriend doesn’t actually care about youLOL he contradicting himself
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #57
Bump
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #59
i dont worry about my rep so i reply multiple times in a row all over the forum to basically anyone
mullatobonemasher
egotistical narcissist
- Joined
- Oct 1, 2025
- Posts
- 699
- Reputation
- 274
new? you joined 2021 bhai
𝕯𝖓𝖆𝖌`
◆Your all my pawns◆ sugarmaxxer| genetic miracle
- Joined
- Oct 18, 2025
- Posts
- 1,247
- Reputation
- 1,449
Dnr probably good thread
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...investor.bridgebio.com
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...pmc.ncbi.nlm.nih.gov
ClinicalTrials.gov
clinicaltrials.gov
Cryptoparek8
Young sensitive man
- Joined
- May 27, 2026
- Posts
- 998
- Reputation
- 2,000
Mirin
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
S
Sick
Remember, they hated you first
- Joined
- Dec 2, 2021
- Posts
- 3,213
- Reputation
- 2,895
in my era all we did was hgh and maybe test and ai, but mostly hgh this other shit is new
ttravisbbicklee
Iron
- Joined
- Jul 30, 2026
- Posts
- 14
- Reputation
- 3
if my weight is 40kg shld i take 10mg or maybe 5-6 at start. thinking bout making capsules bymyself with 1kg taurine and 1gram of infig
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #66
bump
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
Navity
Check bio for discord
- Joined
- Dec 22, 2025
- Posts
- 7,112
- Reputation
- 18,566
Great thread!
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #68
Yeah thanks bro
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #69
bump
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
ShinjiCHAD
Iron
- Joined
- May 4, 2025
- Posts
- 23
- Reputation
- 20
bump.
source?
source?
roidfaper66
Iron
- Joined
- Feb 19, 2026
- Posts
- 96
- Reputation
- 37
I think its way to complicated for medium iq ppl to build themselves a good stack with fgfr3 inhibs
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
rsj
Zephir
- Joined
- Jun 17, 2026
- Posts
- 1,893
- Reputation
- 1,550
- OP
- #72
It’s just the name of a book series that simplifies topics
mason35
Nd heightcell nazi
- Joined
- Jan 17, 2026
- Posts
- 301
- Reputation
- 138
Great thread very helpful
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
mason35
Nd heightcell nazi
- Joined
- Jan 17, 2026
- Posts
- 301
- Reputation
- 138
Where can I find user testimony’s of fgfr3 inhibs?
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
C
Cope Maxxing
Iron
- Joined
- Apr 23, 2025
- Posts
- 185
- Reputation
- 47
I could find sources for everying else but vosoritide bro no one has it not even on indiamart, does anyone have a source?
FGFR3 Inhibitors For Dummies
special thanks to Punjabi Waffen for inspiration and research
What is FGFR3? FGFR3 (Fibroblast growth factor receptor 3) is the body’s built-in brake pedal for bone growth. It slows the cartilage cells inside your growth plates, so inhibiting it takes some pressure off the brake and lets long bones grow faster.
What are some FGFR3 inhibitors? Erdafitinib, Infigratinib, Vosoritide and TYRA-300 (not all will be mentioned due to lack of evidence for height).
FGFR3 inhibitors information:
Erdafitinib:
Erdafitinib is an oral pan-FGFR inhibitor that blocks FGFR1-4, including FGFR3. It is mainly a cancer drug, so unlike more selective options it also hits pathways outside FGFR3.
Evidence: it has strong human evidence as a targeted treatment for FGFR-altered urothelial cancer, but the relevant height angle comes from FGFR3’s role as a brake on growth-plate activity, not from a dedicated height trial.
Infigratinib:
Infigratinib is a oral pan FGFR1-3 inhibitor, one of the main signals that tells your growth plates to slow down. The dose used in the growth study was 0.25 mg for every kilogram of bodyweight per day, which is far lower than the doses once used for cancer.
Evidence: In children with achondroplasia, the highest study dose increased yearly growth by around 2.5 cm after 18 months. It also improved height relative to other children with achondroplasia and slightly improved body proportions.
Vosoritide:
Vosoritide is a daily injection that helps cancel out FGFR3’s “slow bone growth” signal. Instead of blocking FGFR3 directly, it boosts a natural growth-plate signal that tells the bone-growth system to keep working.
Evidence: It is the proven and FDA-approved option for children with achondroplasia whose growth plates are still open. In the main trial, it added about 1.6 cm per year of extra growth compared with placebo.
TYRA-300:
TYRA-300 is a once-daily pill designed to block FGFR3 specifically. Unlike older FGFR drugs, it is meant to leave FGFR1, FGFR2, and FGFR4 alone, which could mean fewer random side effects outside the growth plates.
Evidence: It has made long bones grow more and improved body proportions in achondroplasia mouse studies. A human Phase 2 achondroplasia study is now testing several daily weight-based doses, but there are not yet human height results to show.
Side effects:
Erdafitinib The big ones are high phosphate, eye/retinal toxicity (like potentially becoming blind), nail damage, dry skin or mouth, diarrhea, mouth sores, fatigue, and hand-foot syndrome. It is the “powerful but messy” FGFR inhibitor because it is not FGFR3-selective and highly potent. Infigratinib At the growth dose, it looked very well tolerated. Reported issues were mainly mild stomach upset, gas, nausea, lower appetite, and lower vitamin D; one person had mildly high phosphate in their blood and needed to pause and lower the dose. No major eye problems, faster growth-plate aging, or worse bone density were seen in that study. Vosoritide The most common ones are redness, swelling, or pain where you inject it, vomiting, low blood pressure shortly after the shot, sweating more, and joint or limb pain. The major downside is that it has to be injected every day. TYRA-300 Nobody knows the full side-effect profile at growth doses yet because the pediatric growth trial is still ongoing. The whole selling point is that FGFR3-only targeting should avoid the high phosphate, eye, skin, and liver problems seen when other FGFR receptors get blocked, but that is still theory until the trial data come out.
Dosing:
Erdafitinib Not 100% settled on. FDA figure is 8 to 9mg once daily is for the cancer dose. People on this forum report using 2 to 4mg daily as a dose for heightmaxxing. Infigratinib 0.25 mg/kg daily Vosoritide 15 mcg/kg daily injection TYRA-300 0.125 to 0.50 mg/kg daily being studied
for the weight based dosing, just convert your weight to kilograms from pounds (if you use pounds to weight instead of kilograms) then multiply your weight in kg by the specific milligram (mg) or microgram (mcg) amount to see how much you need to take daily.
Picking a FGFR3 inhibitor (click on image):
Sourcing:
For sourcing Erdafitinib, Infigratinib and Vosoritide you can get them all from the same places. If you have a Whatsapp or Telegram vendor with one of these they probably have all three. If you wanna get it from a website with a ton of pharma (like indiamart for example) just make an inquiry as they may not have a listing for it, but you can definitely find it if you ask. For something like TYRA-300 you either need to get a vendor on a chat-app that will make the capsules or tablets for you and ship it to you. You could also order the raw powder from many chemical websites and make the capsules or press the tablets yourself with a machine.
Research:
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory...
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia - PMC
Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
ClinicalTrials.gov
